Date:1/14/2010

tation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE ERT

RELATED LINKS
http://www.ert.com

'/>"/>

SOURCE ERT Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
2. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
3. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
4. European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis
5. MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009
6. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
7. Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting
8. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
9. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
10. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
11. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class